Reformulated B<scp>ene</scp>F<scp>ix</scp>^®: efficacy and safety in previously treated patients with moderately severe to severe haemophilia B

<jats:p><jats:bold>Summary.  </jats:bold> B<jats:sc>ene</jats:sc>F<jats:sc>ix</jats:sc><jats:sup>®</jats:sup>, the only recombinant factor IX (FIX), has been reformulated. The reformulation involves a change in diluent and allows for more concentrated infusions of recombinant FIX. A double‐blind, randomized, pharmacokinetic (PK) crossover study demonstrated that reformulated B<jats:sc>ene</jats:sc>F<jats:sc>ix</jats:sc> was bioequivalent to original B<jats:sc>ene</jats:sc>F<jats:sc>ix</jats:sc> and follow‐up PK evaluation after 6 months of treatment demonstrated the PK stability of reformulated B<jats:sc>ene</jats:sc>F<jats:sc>ix</jats:sc> after multiple exposures. Favourable efficacy and safety profiles, consistent with those already well‐established for original B<jats:sc>ene</jats:sc>F<jats:sc>ix</jats:sc>, were observed: 81.1% of haemorrhages resolved with only a single infusion; 85.3% of initial treatment response ratings were Excellent or Good; more than half of the subjects using reformulated B<jats:sc>ene</jats:sc>F<jats:sc>ix</jats:sc> for routine prophylaxis (11 of 17, 64.7%) had no spontaneous haemorrhages during their 6–12 month course of prophylactic treatment, with an overall spontaneous bleeding rate of 0.72 year<jats:sup>−1</jats:sup>; and for the single surgical procedure (knee washing), treatment was rated Useful. In addition, there was no FIX inhibitor development, allergic‐type manifestations, or thrombogenic complications with more than 1100 infusions (nearly 5.2 million IUs) administered in this trial. All efficacy and safety outcomes from this study were achieved with more concentrated recombinant protein infusions than that possible with original B<jats:sc>ene</jats:sc>F<jats:sc>ix</jats:sc>, and utilization of the 2000 IU per vial dosage strength, newly introduced with the reformulated product, was high (>62%). The reformulation of B<jats:sc>ene</jats:sc>F<jats:sc>ix</jats:sc> allows smaller delivery volumes and an increased choice of dosage strengths without altering the PK properties (including incremental recovery and half‐life) or the established efficacy and safety profile of recombinant FIX.</jats:p>